INTRODUCTION

Acute limb ischemia (ALI), defined as a sudden compromise in limb perfusion with a potential threat to limb viability, is a common vascular emergency [1]. Atherosclerotic thromboembolic disease commonly plays a major etiologic role; however, rarely malignant disorders may lead to vascular thrombosis and ALI. Occurrence of arterial thrombosis as a complication of chemotherapy and specifically, its onset secondary to treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) is well known [2-4]. However, ALI as an initial presenting feature of acute leukemia is rare. Due to the rarity of this presentation, there is a scarcity of prospective randomized data to optimally guide the management of these patients. Current knowledge is mainly based on isolated cases. We report our experience managing a patient who presented with ALI and was found to have occult leukemia. A review of all cases with ALI as a presenting feature of acute leukemia is also presented.

Key Words: Acute limb ischemia, Cold leg, Arterial thrombosis, Acute promyelocytic leukemia, Acute myeloid leukemia-M3

CASE

A 75-year-old woman presented to the emergency room with two weeks’ duration of acute onset right foot numbness/tingling. Symptoms progressed with increased numbness and worsened right thigh pain over the day prior to her presentation, inciting her to seek medical attention. Past medical history was only significant for arthritis. The patient was not on any home medications. There was no personal or family history of peripheral arterial disease, cardiovascular disease, malignancy or thromboembolism. Her review of systems was positive for the presence of night sweats for the past two years. Her exam revealed absence of palpable femoral and distal pulses on the right lower extremity. The left lower extremity had intact femoral/
Table 1. Reported cases with acute limb ischemia as a presenting feature of acute leukemia

| Author                          | Age (y) | Sex | Leukemia type | Findings                                                                 | Management                                                                 | Outcome      |
|---------------------------------|---------|-----|---------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------|
| Brinson and Garcia, 1984 [5]    | 36      | M   | ALL           | Occlusion of infra-renal aorta; CIA. Thrombus composed of fibrin and leukemic cells | Aortic thrombectomy; chemotherapy                                      | Non-fatal    |
| Redmond et al., 1993 [7]        | 28      | M   | ALL           | Thrombosis of Rt. EIA, profunda femoris and three lower leg arteries       | Thrombolysis; heparin; Rt. BKA                                          | Limb loss    |
| Chang et al., 2003 [6]          | 46      | M   | AML (no subtype) | Occlusion of Lt. ATA, PTA; gangrenous Lt. 5th toe                        | Thrombolysis; platelet-pheresis; chemotherapy; Lt. BKA                   | Limb loss, fatal |
| Reisch et al., 2007 [8]         | 39      | F   | AML (M1)      | Recurrent occlusion of Rt. CIA, EIA; Lt. CFA, PFA, SFA; Lt. leg compartment syndrome. White thrombus with leukemic blasts | Multiple thrombectomies; fasciotomy; heparin; AT III; Rt. thigh amputation; chemotherapy | Limb loss    |
| Overton et al., 2012 [9]        | 57      | F   | AML (M1)      | Bilateral common iliac artery disease, total occlusion on left. Thrombus made of fibrin mesh with entrapped leukemic cells | Multiple bilateral thrombectomy-embolectomies; heparin; femoro-popliteal bypass; clopidogrel; chemotherapy; Lt. AKA | Limb loss, fatal |
| Kootte et al., 1986 [10]        | 42      | F   | AML (M2)      | Occlusion of aorta; Rt. CFA                                               | Aortic thrombectomy                                                      | Fatal        |
| Campbell and Mitchell, 1994 [11]| NA      | NA  | AML (M2)      | SFA stenosis, obstruction                                                 | Chemo                                                                    | Non-fatal    |
| Mahaix et al., 1996 [12]        | 42      | NA  | AML (M2)      | Rt. PopA thrombosis                                                      | Thrombolysis; multiple thrombectomy-embolectomies; Rt. AKA              | Limb loss    |
| Malnick et al., 1998 [13]       | 40      | F   | AML (M5)      | Occlusion of Rt. CFA; functional protein C deficiency. Thrombus with no leukemic cells within | Multiple thrombectomies; heparin; oral anticoag; chemotherapy           | Fatal        |
| Kafetzakis et al., 2007 [14]    | 57      | M   | AML (M5)      | Occlusion of Rt. CIA. White clot with leukemic cells                      | Heparin; leukapheresis; chemo; open thromboembolectomy                  | Non-fatal    |
| Mar et al., 2013 [15]           | 63      | M   | AML (M5)      | Near-complete occlusion of infra-renal aorta; DIC. Fibrin thrombus with leukemic cells | Heparin; aortic thrombectomy                                             | Fatal        |
| Jetha, 1981 [16]                | 25      | F   | APL (M3)      | NA                                                                       | Chemo                                                                    | Fatal        |
| Fass et al., 1992 [17]          | 10      | M   | APL (M3)      | Recurrent thrombosis of CFA; SFA; PopA. White thrombus with leukemic cells | Multiple thrombectomies; AKA                                             | Limb loss    |
| Rolston et al., 1998 [18]       | 16      | M   | APL (M3)      | Occlusion of Lt. EIA; PE; intra-ventricular thrombus                      | Surgical thrombectomy; ATRA; chemotherapy                               | Non-fatal    |
| DiGiovanni et al., 1999 [19]    | 16      | M   | APL (M3)      | Acute arterial thrombosis –Lt. SFA. PE. 'Whitish material' retrieved from Lt. femoral artery | Femoral embolectomy; ATRA; chemo; oral anticoag                          | Non-fatal    |
| Kalk et al., 2003 [20]          | 47      | F   | APL (M3)      | Total occlusion –Lt. PopA                                                 | ATRA; chemo; toe amputation                                             | Non-fatal    |
| Posacioglu et al., 2003 [21]    | 39      | M   | APL (M3)      | Total occlusion –Lt. CIA; necrotic Lt. big toe. White clot retrieved from femoral artery | Open multiple thrombectomies; heparin; ATRA                               | Fatal        |
| Belizna et al., 2009 [22]       | 51      | M   | APL (M3)      | Total occlusion –Lt. femoral, popliteal and peroneal artery; DIC          | Surgical thromboembolectomy; chemotherapy                               | Limb loss, fatal |
| Trotter-Tellier et al., 2014 [23]| 52     | F   | APL (M3)      | Recurrent thrombosis of Lt. axillary artery+PE +recent DVT                | Heparin; multiple thrombolysis; open thrombectomy; Lt. carotido-humeral bypass; ATRA | Non-fatal    |
| Our case 2015                   | 75      | F   | APL (M3)      | Recurrent acute arterial thrombosis –Rt. CIA                             | Heparin; ATRA; open multiple thrombectomies                              | Fatal        |

M, male; F, female; ALL, acute lymphoblastic leukemia; CIA, common iliac artery; chemo, chemotherapy; Rt., right; Lt., left; EIA, external iliac artery; BKA, below-knee amputation; AML, acute myeloid leukemia; AFA, anterior tibial artery; PFA, posterior tibial artery; CFA, common femoral artery; PFA, profunda femoris artery; SFA, superficial femoral artery; AT III, anti-thrombin III; AKA, above-knee amputation; NA, not available; PopA, popliteal artery; +, present; -, absent; DIC, disseminated intra-vascular coagulation; APL, acute promyelocytic leukemia; PE, pulmonary embolism; ATRA, all trans retinoic acid; DVT, deep venous thrombosis.
popliteal/pedal pulses. The right foot was slightly cooler to touch than the left foot; her sensory exam was dulled but intact in the right foot. Motor function throughout the right lower extremity was widely intact. There was no discoloration of skin overlying the right foot and the capillary refill was about two seconds. The rest of the physical examination was unremarkable. Initial laboratory values were remarkable for white blood cell (WBC) count of 43.5×10^9/L, platelet count 65×10^9/L, hemoglobin 8.6 g/dL and hematocrit of 25%. Serum chemistry, chest radiograph and electrocardiogram were unremarkable. Peripheral smear showed presence of 90% blasts, 1 Auer rod, teardrop cells, normochromic red cells, and immature red cells. APL was suspected and ATRA therapy was initiated. Concomitantly, a computed-tomographic angiogram (CTA) was obtained and a bone marrow biopsy was performed. CTA revealed occlusive thrombus of the right common iliac artery (Fig. 1). Given the vascular exam and CTA findings, the patient was urgently brought to the operating room (OR).

In the OR, a right femoral artery cut-down was performed, and right ilio-femoral artery thrombectomy was attempted however, we were unable to successfully pass a 4 or 5F Fogarty balloon catheter more than 8-10 cm proximally, and therefore a left-to-right femoral-femoral bypass using an 8 mm ringed Propaten graft (W.L. Gore and Associates, Flagstaff, AZ, USA) was performed. The patient regained palpable pedal pulses with resolution of her lower extremity symptoms.

On the evening of the first post-operative day, the patient developed acute recurrent foot numbness; exam revealed a cold foot with loss of pulses. She was emergently brought back to the OR and was found to have a “white clot” in her common femoral artery where her graft was anastomosed and additional “white clot” in her bypass graft. Thrombectomy was performed and a clot-free run off was confirmed. Retrieved thrombus material was not sent for histopathologic examination. In addition, when performing our thrombectomies at this point, we again attempted to pass our Fogarty balloon catheter proximally—this time we were able to successfully thrombectomize the right sided native inflow artery. Angiography now confirmed patency of fem-fem bypass and the anastomoses, as well as patency of the right iliac artery system. We elected to leave the fem-fem bypass in place, assuming it would eventually thrombose due to competitive flow. The patient again had resolution of symptoms with intact bilateral lower extremity pulse exam.

Concomitant hypercoagulable work-up including echocardiography and review of her prior CTA failed to demonstrate any clear embolic source. The bone marrow biopsy flow-cytometry confirmed the diagnosis of CD-34- and human leukocyte antigen-DR-negative acute myeloid leukemia (AML) (Fig. 2). Bone marrow fluorescence in-situ hybridization (FISH) result was negative for the t(15:17) translocation seen in the classic French-American-British M3 subtype [24]. FISH analysis for variant subtypes of M3 was not obtained. Cytogenetics was normal female karyotype. A presumptive diagnosis of t(15:17) negative variant of APL was made [25]. ATRA therapy was discontinued at this point.

Within the next 24 hours, however, the patient developed acute onset of bilateral lower extremity pain and...
paralysis. She had cool, pulseless legs; and imaging confirmed occlusion of the femoro-femoral bypass, but also with thrombus occluding bilateral common femoral arteries. She was again returned emergently to the OR, and underwent bilateral ilio-femoral thrombectomies and excision of her femoro-femoral bypass with patching of bilateral common femoral arteries. Again, pulses and exam was restored to baseline. Of note, at this time the patient’s WBC count had peaked at over 80x10^9/L. Within the next 15 hours, she again developed bilateral lower extremity numbness, right sided paralysis, and loss of bilateral pulses distally. She was once again returned to the OR emergently, where she underwent bilateral ilio-femoral thrombectomies, resection of her right common femoral artery with dacron interposition grafting, and bovine pericardial patch angioplasty of the left common femoral artery. Completion angiography once again confirmed widely patent bilateral common femoral arteries and bifurcations (Fig. 3). The patient was maintained on therapeutic anti-coagulation through the entire clinical course.

Within the next 12 hours however; the patient once again developed right foot and leg pain and numbness, as well as paralysis with loss of pulses. At this point, further operative attempts were felt to be futile. After extensive discussions with the patient, her family, the hematologists, as well as the opinion of a national cancer center, the patient elected to go to inpatient hospice, where she subsequently expired one week later.

**DISCUSSION**

Development of malignancies is commonly associated with disturbances in normal hemostasis [26]. Acute leukemias are known to be more commonly associated with bleeding and disseminated intravascular coagulation than with thrombosis. However, recent studies indicate that thrombotic events may be more prevalent in acute leukemias than previously reported [27-29]. The incidence of venous thromboembolism in untreated leukemia patients is ~2%-3%, however occurrence of arterial thrombosis in these patients is not common [27,29]. Thrombogenic properties of leukemic cells are attributable to expression of procoagulant activities (PCA) including tissue factor (TF) and cancer procoagulant, fibrinolytic and proteolytic mediators, as well as inflammatory cytokines leading to activation of the clotting cascade [26,30,31]. Additionally, cancer chemotherapy may also predispose leukemia patients to thrombosis by direct toxic effects on vascular endothelium, direct induction of tumor cell TF, and a decrease in physiologic anticoagulants [30]. Reports describing arterial thrombosis associated with leukemia have described these thrombi as “white thrombi”. These thrombi are platelet- and fibrin-rich, but lack erythrocytes unlike “red thrombi”. The exact mechanism remains unknown but it is hypothesized that severe leukocytosis and abnormal accumulation of lymphocytes, may trigger leukemic cell sedimentation followed by aggregation of platelets to complete the clot formation which eventually leads to arterial occlusion and ischemia [14,17,19]. Pre-clinical studies have proven that conventional thrombolytic therapy is more effective on the “red” thrombus compared to the fibrin-rich “white” thrombus [32].

In an observational cohort study, 13 of 379 (3.4%) newly diagnosed leukemia patients were found to have venous or arterial thrombosis as the initial presentation. Four patients had arterial thrombosis manifesting as ischemic stroke, but none presented with ALI [27]. In another retrospective review of 63 APL patients, 13 presented with thrombosis, however none presented with ALI [28]. Only a handful of cases of occult leukemia initially presenting as acute thrombosis of major arteries have been reported. Our literature search revealed twenty such cases, including our
case (Table 1). Of these twenty cases, two were associated with acute lymphoblastic leukemia and eighteen (90%) were associated with AML. Among the AML subtypes, APL (M3) was the most frequent (50%, 9/18 cases), followed by M5 (17%), M2 (17%), and M1 (11%) subtypes presenting with ALI (Table 1). This was similar to findings from the above mentioned study, which reported that APL was the most frequently associated subtype with arterial thrombosis as an initial presentation [27]. Recently, in a review of all cases of APL-associated thrombosis, 94 cases were identified [3]. Only six of the 94 patients (6%) had associated major arterial thrombosis, of which, four had ALI as an initial feature of occult APL. The thrombogenic property of APL is attributed to hyper-expression of PCA, including TF, in the leukemic cells [26,30].

APL is a distinct subtype of acute leukemia characterized by a balanced reciprocal translocation - t(15:17) resulting in formation of the leukemogenic fusion gene promyelocytic leukemia/retinoic acid receptor (PML/RARα) [25,26,30]. Studies have identified variants of M3 without the classical t(15:17) translocation as well as without the PML/RARα fusion gene [25]. Interestingly a higher incidence of coagulopathy and hemorrhage related deaths have been reported in APL patients with M3-variants compared to classical M3 patients [25]. Our patient presented with arterial thrombosis and leukocytosis as the sole presenting feature of the APL. We postulate that this was a variant subtype of M3, as the classic t(15:17) translocation was not present on the FISH analysis. No further FISH testing was obtained to confirm the rare variant subtypes of APL [25]. Presence of M3-variant and a WBC>10×10⁹/L were indeed found to be significant risk factors for thrombosis in a previously reported study [33].

Management of acute leukemia presenting as ALI requires a multidisciplinary care approach. In view of threat to limb viability, vascular management generally takes precedence; however, concomitant medical management should be initiated promptly. A hematology consult should be obtained along with a peripheral smear exam. Aggressive supportive treatment using blood products should be initiated to maintain target platelet count above 30×10⁹/L and fibrinogen level above 1.5 g/L [34]. Presumptive diagnosis of APL can be made from presence of characteristic clinical presentation, peripheral smear and bone marrow biopsy findings [34,35]. Targeted bi-functional therapy using ATRA should not be delayed while waiting for cytogenetic or molecular confirmation of APL in order to prevent hemorrhage related deaths [3,27,34-36]. The use of ATRA has been shown to induce complete remission as well as rapid reversal of coagulopathy in APL patients [26,34,35,37]. ATRA is also effective in treating elderly patients above 60 years with co-morbidities [38]. Paradoxically, incidence of thrombosis in APL has increased in the post-ATRA era [2]. This may be attributed to ATRA-induced differentiation syndrome and ATRA-associated sustenance of a low-level pro-thrombotic state [26,31,39]. In our patient, ATRA was started immediately once APL was suspected however, it was stopped once bone marrow FISH results were negative for t(15:17) translocation. We postulate that the initial thromboses as well as subsequent recurrent episodes were not associated with ATRA in our case.

The initial surgical evaluation of these patients should follow the inter-society consensus for the management of peripheral arterial disease recommendations and include a clinical determination of limb viability and timing of intervention based on clinical classification of ALI [1,40]. An immediate Doppler assessment of peripheral pulses, measurement of ankle-brachial index and prompt evaluation by a vascular specialist should follow [1]. Degree of limb viability and associated co-morbidities greatly influence the decision whether to manage these patients operatively or non-operatively. No randomized studies are available due to the rarity of this presentation, however experience from the limited number of cases reported (Table 1) and from studies involving patients with solid malignancies presenting with ALI, may guide decision making [4,41]. A conservative management approach has been advocated by some based on studies showing poor outcomes with post-operative mortality as high as 80%-100% when malignancy associated ALI is treated surgically [42,43]. In contrast, recent retrospective studies have favored an early surgery-based limb salvage approach in malignancy associated ALI [4,41]. Mouhayar et al. [41] reported a 47% amputation free survival in cancer patients with ALI when treated surgically. Similarly, Tsang et al. [4] also reported a one-year survival of 44% and a 37% limb-loss rate favoring early operative limb salvage. Our review of reported cases of occult leukemia presenting with ALI revealed that 75% (15/20) patients underwent operative management; almost half (45%, 7/15) of these patients met with a fatal outcome and almost one-fifth (20%, 3/15) of patients progressed to limb loss. About a half (53%, 8/15) of these patients developed recurrent thrombosis and required multiple re-thrombectomies with bypass grafting (Table 1). Our patient also had a fatal outcome after developing multiple recurrences of thrombosis involving bilateral lower limb vessels as well as the femoral-femoral bypass graft and taken to the OR multiple times. The recurrent thrombosis was not a result of a technical or mechanical failure as the patency of the peripheral vasculature was assured by clinical improvement, return of distal pulses as well as satisfactory return of distal flow on completion angiograms.
after each operative intervention (Fig. 3).

In summary, acute leukemia should be included in the differential diagnoses of patients presenting with ALI without an obvious etiology. A multidisciplinary approach including a prompt initiation of aggressive supportive treatment is recommended. If APL is suspected, ATRA induction therapy should be started immediately. Managing the ALI in these patients is an added challenge and decision regarding when to operate should be individualized. In most cases, early surgical intervention may be prudent, however outcome is guarded secondary to likelihood of recurrent thrombosis and increased risk of limb-loss or fatality. Vascular surgeons and hematologists should discuss this in great details with the patient and/or family members to optimally guide decision making.

REFERENCES

1) Norgren L, Hiatt WR, Dormandy JA, Neher MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S1-S75.
2) Breccia M, Avvisati G, Latagliata R, Carmosino I, Guarini A, De Propris MS, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007;21:79-83.
3) Rashidi A, Silverberg ML, Conkling PR, Fisher SI. Thrombosis in acute promyelocytic leukemia. Thromb Res 2013;131:281-289.
4) Tsang JS, Naughton PA, O’Donnell J, Wang TT, Moneley DS, Kelly CJ, et al. Acute limb ischemia in cancer patients: should we surgically intervene? Ann Vasc Surg 2011;25:954-960.
5) Brinson RR, Garcia GJ. Acute lymphoblastic leukemia manifested as aortic occlusion. Am J Med 1984;77:385-387.
6) Chang VT, Aviv H, Howard LM, Padberg F. Acute myelogenous leukemia associated with extreme symptomatic thrombocytoysis and chromosome 3q translocation: case report and review of literature. Am J Hematol 2003;72:20-26.
7) Redmond EJ, Welch M, Durrans D, Carr HM, Chasty R, Yin JA, et al. Acute ischaemia of the lower limb: an unusual presenting feature of acute lymphoblastic leukaemia. Eur J Vasc Surg 1993;7:750-752.
8) Reisch N, Roehnisch T, Sadeghi M, Greiner L, Regenbogen C, Rieger J, et al. AML M1 presenting with recurrent acute large arterial vessel thromboembolism. Leuk Res 2007;31:869-871.
9) Overton J, Nicklin A, Eleftheriou P, Frith D, Gravante G, Sapsford W. Recurrent acute lower-limb ischemia with multiple organ infarctions secondary to acute myeloid leukaemia M1. Ann Vasc Surg 2012;26:1128.e1121-e1125.
10) Koote AM, Thompson J, Bruijn JA. Acute myelocytic leukemia with acute aortic occlusion as presenting symptom. Acta Haematol 1986;75:120-121.
11) Campbell J, Mitchell CA. Acute leg ischaemia as a manifestation of the hyperleukocytosis syndrome in acute myeloid leukaemia. Am J Hematol 1994;46:167.
12) Mataix R, Gómez-Casares MT, Campo C, Jiménez S, Malcorra JJ. Acute leg ischaemia as a presentation of hyperleukocytosis syndrome in acute myeloid leukaemia. Am J Hematol 1996;51:250.
13) Mahnick SD, Ben-David D, Shtalrid M, Leichman I, Schwartz H, Shoeger ZM. Acute femoral artery thrombosis associated with functional protein C deficiency as the presenting manifestation of acute monocytic leukemia. South Med J 1998;91:663-664.
14) Kafetzakis A, Foundoulakis A, Ioannou CV, Stavroulaki E, Koutsopoulos A, Katsamouris AN. Acute lower limb ischemia as the initial symptom of acute myeloid leukemia. Vasc Med 2007;12:199-202.
15) Mar N, Gorgan MA, Dailey ME, Vredenburgh JJ. Blue toes and a new pair of shoes---challenges in diagnosis and treatment of acute myelogenous leukemia. Am J Hematol 2013;88:1090-1093.
16) Jetha N. Promyelocytic leukemia with multiorgan infarctions and large-vessel thrombosis. Arch Pathol Lab Med 1981;105:683-684.
17) Fass R, Haddad M, Zaitov R, Sandbank Y, Yaniv I, Cohen LJ, et al. Recurrent peripheral arterial occlusion by leukemic cells sedimentation in acute promyelocytic leukemia. J Pediatr Surg 1992;27:665-667.
18) Rolston DD, Rubin S, Topolsky D, Styler M, Crilley P. Arterial occlusions as a presenting feature of acute promyelocytic leukemia. Am J Oncol 1998;21:436-437.
19) DiGiovanni RJ Jr, Crilley P, Kerstein MD. Peripheral arterial occlusion in acute promyelocytic leukemia. Cardiovasc Surg 1999;7:258-260.
20) Kalk E, Goede A, Rose P. Acute arterial thrombosis in acute promyelocytic leukaemia. Clin Lab Haematol 2003;25:267-270.
21) Posacioglu H, Apaydin AZ, Buyukkececi F, Soydan S, Durmaz I. Recurrent peripheral arterial occlusion in acute promyelocytic leukemia. EJVES Extra 2003;6:100-102.
Recurrent Arterial Thrombosis in Leukemia

22) Belizna C, Pistorius MA, Planchon B. Lethal limb ischaemia in leukaemia. Case report and review of the literature. J Thromb Thrombolysis 2009;28:354-357.
23) Trottier-Tellier F, Durand M, Kolan C, Wistaff R, Nguyen PV, Laskine M. Recurrent arterial and venous thromboemboli as initial presentation of acute promyelocytic leukemia. J Clin Med Res 2014;6:388-391.
24) Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group. Ann Intern Med 1985;103:620-625.
25) Sucić M, Zadro R, Burazer B, Labar B, Nemet D, Mrsić M, et al. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants. J Hematother Stem Cell Res 2002;11:941-950.
26) Falanga A, Barbu T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008;34:204-210.
27) De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti I, Fanchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005;3:1985-1992.
28) Mitrovic M, Suvajdžić N, Elezović I, Bogdanović A, Djordjević V, Miljic P, et al. Thrombotic events in acute promyelocytic leukemia. Thromb Res 2015;135:588-593.
29) Ziegler S, Sperr WR, Knöbl P, Lehr S, Weltermann A, Jäger U, et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005;115:59-64.
30) Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbu T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res 2007;120 Suppl 2:S99-S106.
31) Tallman MS, Lefèbvre P, Baine RM, Shoji M, Cohen I, Green D, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004;2:1341-1350.
32) Kirchhoff K, Welzel T, Mecke C, Zoubaa S, Sartor K. Differentiation of white, mixed, and red thrombi: value of CT in estimation of the prognosis of thrombolysis phantom study. Radiology 2003;228:126-130.
33) Montesinos P, de la Serna J, Vellenga E, Rayon C, Bergua J, Parody R, et al. Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA96 and LPA99 protocols. Am Soc Hematol 2006;108:1503.
34) Tallman MS1, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009;114:5126-5135.
35) Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol 2012;87:596-603.
36) Watts JM, Tallman MS. Acute promyelocytic leukemia: what is the new standard of care? Blood Rev 2014;28:205-212.
37) Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 2010;125 Suppl 2:S51-S54.
38) Finsinger P, Breccia M, Minotti C, Carmosino I, Girmenia C, Chisini M, et al. Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. Ann Hematol 2015;94:195-200.
39) Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 1996;20:435-439.
40) Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-538.
41) Mouhayar E, Tayar J, Fasulo M, Aoun R, Massey M, Abi-Aad S, et al. Outcome of acute limb ischemia in cancer patients. Vasc Med 2014;19:112-117.
42) Javid M, Magee TR, Galland RB. Arterial thrombosis associated with malignant disease. Eur J Vasc Endovasc Surg 2008;35:84-87.
43) El Sakka K, Gambhir RP, Halawa M, Chong P, Rashid H. Association of malignant disease with critical leg ischaemia. Br J Surg 2005;92:1498-1501.